Ultraviolet-A and Riboflavin Treatment for Infectious Keratitis

Infectious Keratitis Clinical Trial

Official title:

Ultraviolet-A and Riboflavin Treatment for Infectious Keratitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01739673
• Other study ID #: iCXL
• Status: Completed
• Phase: N/A
• Start date: August 2011
• Est. completion date: July 2014

Study information

• Verified date: August 2015
• Source: Cxlusa
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is to evaluate the efficacy of ultraviolet-A (UVA) and riboflavin application (also often referred to as corneal collagen crosslinking) as a method to enhance treatment of infectious keratitis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 13
• Est. completion date: July 2014
• Est. primary completion date: July 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subjects must be 18 years of age or older.

2. Ability to provide written informed consent.

3. Likely to complete all study visits.

4. Subjects must have one eye that with a diagnosis of infectious keratitis.

Exclusion Criteria:

1. A corneal perforation.

2. Descemetocele.

3. Pregnancy or breastfeeding.

4. Active Herpes corneal disease.

5. Patient is unwilling or unable to comply with a medication regimen and follow up appointments.

Related Conditions & MeSH terms

• Communicable Diseases
• Infection
• Infectious Keratitis
• Keratitis

Intervention

Other:
• Ultraviolet-A and riboflavin

Locations

Country	Name	City	State
United States	Corneal Consultants of Colorado, PC	Littleton	Colorado
United States	Center for Excellence in Eye Care	Miami	Florida
United States	Minnesota Eye Consultants	Minneapolis	Minnesota
United States	Ophthalmology Associates	Saint Louis	Missouri
United States	Schwartz Laser Eye Center	Scottsdale	Arizona
United States	Davidorf Eye Group	West Hills	California

Sponsors (1)

Lead Sponsor	Collaborator
Cxlusa

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Resolution of Signs and Symptoms of Infectious Keratitis		Subjects will be followed until resolution of signs and symptoms, an expected average of 8 weeks